Ziff Davis Media Seeks Bankruptcy; Ad Revenue Down In filing for bankruptcy, the publisher of technology and video game magazines cited a decrease in revenue from print advertising and subscriptions.... Read Full Article Music Review: At Avant-Garde Jazz Series, Rashied Ali And A Reunion The Sculptured Sounds Music Festival offered an evening of adventurous jazz that yielded mostly positive results and had enough propulsion to shake off whatever wasn?t working.... Read Full Article In Colombia, A Plan To Hand Hostages To Venezuela Stalls The powerful Revolutionary Armed Forces of Colombia promised two weeks ago to free two former Colombian politicians but have not yet disclosed their location.... Read Full Article The Soul In The New Machines An exhilarating new show at the Museum of Modern Art makes the case that through the mechanism of design, scientific advances of the last decade have at least opened the way to unexpected visual pleas... Read Full Article Disney Inquiry On Pixar Grants Finds No Misconduct By Jobs Disney concluded an internal investigation and cleared Steven P. Jobs of any misconduct in issuing backdated stock options at Pixar.... Read Full Article |
Ranbaxy NewsAstraZeneca Settles Ranbaxy LawsuitAstraZeneca shares soared on news that an agreement with Ranbaxy Laboratories will delay the release of a generic competitor to its best-selling heartburn drug for six years.Read Full Article World Business Briefing: India: Profit Doubles at Drug MakerThe Indian pharmaceutical company Ranbaxy Laboratories said its profit in the latest quarter more than doubled from a year ago, helped by robust sales in Europe and huge gains in foreign exchange transactions. Net profit at Ranbaxy rose to 2.66 billion rupees ($65 million), from 1.22 billion rupees ($29 million) in the quarter a year earlier. The growth rate, however, drops to 53 percent if the earnings numbers are adjusted against about 1 billion rupees in net gains the company made from foreign exchange transactions, said Malvinder Singh, the chief executive. More than half of Ranbaxy’s sales come from overseas markets other than the United States. Sales rose 12.3 percent, to 16.24 billion rupees ($395 million).Read Full Article World Business Briefing | Europe: Germany: Bid to Acquire Drug Maker’s Generic UnitAn Indian drug maker, Ranbaxy Laboratories, said it had submitted a bid for the generics unit of the German drug maker Merck but did not disclose how much it was offering. Analysts say Merck’s generics unit could be worth as much as 5 billion euros ($6.6 billion). Merck said last month that it had started contacting companies that might be interested in acquiring its generics drugs unit. Two companies, Ranbaxy and the Actavis Group of Iceland, have publicly expressed an interest. Merck is based in Darmstadt.Read Full Article F.D.A. Searches Drug Maker OfficesThe generic drug developer Ranbaxy Laboratories of India said Thursday that federal agents had searched its offices and a manufacturing facility in New Jersey.Read Full Article External News for: ranbaxyRanbaxy recalls over 4000 cartons of acne drug in US - Economic TimesRanbaxy recalls over 4000 cartons of acne drug in USEconomic TimesNEW DELHI: Ranbaxy Laboratories has initiated a voluntary recall of 4348 cartons of its best-selling drug Sotret (isotretinoin, 40 mg) used to treat acne in ...Ranbaxy Voluntarily Recalls One Lot of Sotret Drug in U.S.Wall Street JournalRanbaxy recalls acne drug from US marketLivemint: Ranbaxy recalls drugs from US marketFinancial ExpressBusiness Standard -Times of Indiaall 11 news articles »Ranbaxy recalls over 4000 cartons of acne drug in US - Economic TimesRanbaxy recalls over 4000 cartons of acne drug in USEconomic TimesNEW DELHI: Ranbaxy Laboratories has initiated a voluntary recall of 4348 cartons of its best-selling drug Sotret (isotretinoin, 40 mg) used to treat acne in ...Ranbaxy Voluntarily Recalls One Lot of Sotret Drug in U.S.Wall Street JournalRanbaxy recalls acne drug from US marketLivemint: Ranbaxy recalls drugs from US marketFinancial ExpressBusiness Standard -Times of Indiaall 11 news articles »Nifty lingers above 5050; Ranbaxy, Wipro, Cipla up - Economic TimesRediffNifty lingers above 5050; Ranbaxy, Wipro, Cipla upEconomic TimesMUMBAI: Indian equities were witnessing a choppy session on Wednesday in line with other Asian peers. IT, realty and pharma stocks moved higher while ...Nifty trades in narrow range with negative biasMoneycontrol.comBulls push Sensex up 4.2 percent (Weekly Market Review)SifySensex manages 2nd week of gainsIndia Infoline.comIndia Business Blog (blog)all 541 news articles »Ranbaxy recalls over 4000 cartons of acne drug in US - Economic TimesRanbaxy recalls over 4000 cartons of acne drug in USEconomic TimesNEW DELHI: Ranbaxy Laboratories has initiated a voluntary recall of 4348 cartons of its best-selling drug Sotret (isotretinoin, 40 mg) used to treat acne in ...Ranbaxy Voluntarily Recalls One Lot of Sotret Drug in U.S.Wall Street JournalRanbaxy recalls acne drug from US marketLivemint: Ranbaxy recalls drugs from US marketFinancial ExpressBusiness Standard -Times of Indiaall 11 news articles »Nifty lingers above 5050; Ranbaxy, Wipro, Cipla up - Economic TimesRediffNifty lingers above 5050; Ranbaxy, Wipro, Cipla upEconomic TimesMUMBAI: Indian equities were witnessing a choppy session on Wednesday in line with other Asian peers. IT, realty and pharma stocks moved higher while ...Nifty trades in narrow range with negative biasMoneycontrol.comBulls push Sensex up 4.2 percent (Weekly Market Review)SifySensex manages 2nd week of gainsIndia Infoline.comIndia Business Blog (blog)all 541 news articles »Ranbaxy: FDA Issues Will Take Long Time To Resolve - Wall Street JournalRediffRanbaxy: FDA Issues Will Take Long Time To ResolveWall Street JournalNEW DELHI (Dow Jones)--Ranbaxy Laboratories Ltd. (500359.BY) will take "a long time" to resolve issues with the US Food and Drug ...Ongoing FDA issues aren't stopping RanbaxyFiercePharmaDaiichi Sankyo to launch Ranbaxy's drugs in Japan soonEconomic TimesIndia Eco Summit: Issues with USFDA to drag on, says RanbaxyBusiness StandardTopNewsall 24 news articles » |
i8news.com |